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Abstract
Background: Pancreatic cancer is a devastating disease characterized by dismal 5-year survival
rates and limited treatment options. In an effort to provide useful models for preclinical evaluation
of new experimental therapeutics, we and others have developed orthotopic mouse models of
pancreatic cancer. The utility of these models for pre-clinical testing is dependent upon
quantitative, noninvasive methods for monitoring in vivo tumor progression in real time. Toward
this goal, we performed whole-body fluorescence imaging and ultrasound imaging to evaluate and
to compare these noninvasive imaging modalities for assessing tumor burden and tumor
progression in an orthotopic mouse model of pancreatic cancer.
Methods:  The human pancreatic cancer cell line XPA-1, engineered for stable, high-level
expression of red fluorescent protein (RFP), was implanted into the pancreas of nude mice using
orthotopic implantation. The tumors were allowed to grow over a period of one to several weeks
during which time the mice were imaged using both fluorescence imaging and ultrasound imaging
to measure tumor burden and to monitor tumor growth.
Results:  Whole-body fluorescence imaging and ultrasound imaging both allowed for the
visualization and measurement of orthotopic pancreatic tumor implants in vivo. The imaging
sessions were well-tolerated by the mice and yielded data which correlated well in the quantitative
assessment of tumor burden. Whole-body fluorescence and two-dimensional ultrasound imaging
showed a strong correlation for measurement of tumor size over a range of tumor sizes (R2 =
0.6627, P = 0.003 for an exposure time of 67 msec and R2 = 0.6553, P = 0.003 for an exposure time
of 120 msec).
Conclusion: Our findings suggest a complementary role for fluorescence imaging and ultrasound
imaging in assessing tumor burden and tumor progression in orthotopic mouse models of human
cancer.
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Background
Pancreatic cancer is a devastating disease with 5-year sur-
vival rates less than 5% [1]. In an effort to provide useful
models for preclinical evaluation of drug therapy, we and
others have developed orthotopic mouse models of pan-
creatic cancer [2-5]. These animal models promise to be
invaluable for the testing of new cancer therapeutics.
Orthotopically growing tumors can metastasize, in a pat-
tern that resembles the clinical behavior of the original
human tumor both in sites of metastasis and frequency of
occurrence [6,7]. Tumor cells transduced and selected for
high expression of fluorescent proteins implanted ortho-
topically can thus be used to visualize both primary and
metastatic tumors [8]. Furthermore, the primary tumor
and subsequent metastasis can be visualized non-inva-
sively by whole body imaging through the skin of the
nude mouse [3]. Such visualization can be a practical and
convenient way to follow tumor growth and metastasis in
real-time.
Other techniques of tumor imaging, including X-ray com-
puted tomography (CT), positron emission tomography
(PET), magnetic resonance imaging (MRI), and ultra-
sound, have been developed for small animal imaging
and are available to investigators. Each technique has its
specific advantages as well as limitations but, in the end,
may be complementary to each other. For instance, we
have previously shown that fluorescent protein imaging
and MRI of pancreatic tumors are complementary and
that there is a strong correlation between the two modali-
ties [9]. Ultrasound imaging involves exposing tissues to
high-frequency ultrasound waves (20–60 MHz in ani-
mals; 2–10 MHz in humans). It is a non-isotopic, nonin-
vasive imaging modality which provides good soft tissue
contrast and yields a high degree of spatial resolution
without a requirement for contrast agents. This noninva-
sive technique produces a dynamic real-time image of the
tissue from which structural and functional information
can be obtained. Ultrasound in mice has been used to
monitor tumor growth in prostate cancer [10,11], mouse
mammary tumors [12], and ovarian cancer [13]. In this
study, we sought to determine if fluorescence imaging and
ultrasound imaging of orthotopic pancreatic tumors
would correlate and potentially be a useful combined
modality for monitoring of tumor growth, off-setting
some of the limitations of each modality used alone.
Methods
Cell Culture
The human pancreatic cancer cell line XPA1 was a gift
from Dr. Anirban Maitra at Johns Hopkins University.
Cells were maintained in RPMI 1640 media supple-
mented with 10% fetal bovine serum (FBS) and 2 mM
glutamine from (Gibco-BRL, Life Technologies, Inc.,
Grand Island, NY). All media was supplemented with
penicillin/streptomycin (Gibco-BRL), L-glutamine
(Gibco-BRL), MEM nonessential amino acids (Gibco-
BRL), sodium bicarbonate (Cellgro, Herndon VA), and
sodium pyruvate (Gibco-BRL). All cell lines were cultured
at 37°C with 5% CO2.
RFP Retroviral Transduction and Selection
The pDSRed-2 vector (Clontech Laboratories, Inc., Palo
Alto, CA) was used for stable expression of red fluorescent
protein (RFP) in the human pancreatic cancer cell line
XPA-1. The pDsRed-2 retrovirus, which also contains a
neomycin resistance gene, was produced in PT67 packag-
ing cells. 20% confluent XPA-1 cells were incubated with
retroviral supernatants of the packaging cells for 24 hours.
Fresh medium was then replenished and the cells were
allowed to grow for another 12 hours. This was repeated
until high levels of RFP expression were observed under
fluorescence microscopy. Cells were then trypsinized and
harvested, and subcultured in selective media containing
Geneticin G418 (Invitrogen Corp., Carlsbad, CA). The
level of G418 was increased in a stepwise fashion from
200 μg/mL to 2000 μg/mL. Clones with high RFP expres-
sion were isolated using cloning cylinders and grown for
10 passages in the absence of G418 to select for stable in
vitro expression of RFP.
Animal Care
Athymic nu/nu nude mice between 4 and 6 weeks of age
were maintained in a barrier facility on high efficiency
particulate air (HEPA)-filtered racks. The animals were fed
with autoclaved laboratory rodent diet (Teckland LM-485;
Western Research Products, Orange, CA). All animal stud-
ies were approved by the UCSD Institutional Animal Care
and Use Committee and conducted in accordance with
the principles and procedures outlined in the NIH Guide
for the Care and Use of Animals.
Orthotopic Tumor Implantation
Orthotopic human pancreatic cancer xenografts from the
pancreatic cancer cell line XPA-1-RFP were established in
nude mice by orthotopic implantation. Orthotopic
implantation was performed with the animals anesthe-
tized by intramuscular injection of 0.02 mL of a solution
of 50% ketamine, 38% xylazine and 12% acepromazine
maleate. The animals were anesthetized and a small trans-
verse incision was made in the left lateral flank through
the skin and peritoneum. The tail of the pancreas was
exposed and 5 × 105 (20 mice) or 2 × 106 (15 mice) XPA-
1-RFP cells were injected into the pancreas in a total vol-
ume of 20 μL of serum-free media and Matrigel (1:1)
using a Hamilton syringe (Sigma-Aldrich). The pancreas
was then returned to the abdomen and the peritoneum
and skin were closed using 6-0 Polysorb surgical suture
(US Surgical Corporation, Norwalk, CT).BMC Cancer 2009, 9:106 http://www.biomedcentral.com/1471-2407/9/106
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Fluorescence Imaging
Mice were imaged 1–2 times per week using the Olympus
OV100 Small Animal Imaging System (Olympus Corp,
Tokyo Japan) containing an MT-20 light source (Olympus
Biosystems, Planegg, Germany) and either the DP71 CCD
camera (Olympus Corp. Tokyo, Japan) for qualitative
color images of tumor implants or with the Hamamatsu
monochrome camera (Hamamatsu Corp, Hamamatsu
City Japan) for quantitative evaluation of fluorescence
intensity. For whole body fluorescence imaging of live
mice, the mice were anesthetized by inhalation of 2–3%
isoflurane with 1% oxygen during the imaging session.
Mice were imaged with their ventral sides towards the
camera, such that images used to determine tumor sizes
were all obtained in the coronal plane. Fluorescence
images were collected at a predetermined series of expo-
sure times using RFP filter sets with an excitation filter of
545/30 and an emission filter of 598/55. All images were
processed for contrast and brightness and analyzed using
ImageJ http://rsb.info.nih.gov/ij/download.html software
and Photoshop Elements-4 (Adobe Systems Inc, San Jose,
CA) software. Tumor margins were determined by ImageJ
software from monochrome fluorescence images using
automated thresholds based on pixel intensity. The
OV100 is calibrated by the manufacturer to display a scale
bar on acquired images. This scale bar is then used to
measure lengths and calculate cross-sectional areas using
either OV100 software or ImageJ software.
Ultrasound Imaging
Ultrasound imaging was performed on the same day as
fluorescence imaging. Mice were anesthetized by inhala-
tion of 2–3% isoflurane with 1% oxygen. Anesthetized
mice were placed on a thermostatically controlled heating
pad to maintain body temperature. Tumors were imaged
with the VisualSonics Vevo™ 770 In Vivo High-Resolution
Micro-Imaging System (VisualSonics Inc, Toronto,
Ontario, Canada). With mice lying on their right sides, an
aqueous ultrasonic gel was applied to the skin overlying
the spleen and subjacent pancreas. A transducer with cen-
tral frequency at 40 MHz, providing axial resolution of 40
μm with a 14.6 mm field of view, was used for imaging of
smaller tumors. A transducer with central frequency at 25
MHz transducer, providing axial resolution of 70 μm with
a 20 mm field of view, was used for larger tumor imaging.
Cine loops of ultrasound image were recorded digitally
and reviewed. An image frame showing the tumor at it's
largest cross-sectional size was selected for analysis. The
largest tumor area in a coronal plane was measured by
manually tracing the margin of the tumor using Vevo 770
software. The software then calculates the area enclosed
within the delineated region. The instrument is calibrated
to allow measurements to be determined accurately.
Correlating fluorescence imaging and ultrasound imaging 
measurements of tumor size
To assess the correlation of fluorescence and ultrasound
imaging modalities for assessment of pancreatic tumor
size and tumor growth, all orthotopically implanted pan-
creatic tumors, from a total of 29 mice, were imaged using
both imaging modalities. Each tumor was imaged in vivo
to determine its size (maximum cross sectional area) in
the coronal plane, as described above. Mice were sacri-
ficed at predetermined times or when the dimensions of
their tumors reached various target size ranges. A subset of
mice were imaged on a weekly basis for four weeks so that
the growth of individual tumors could be followed. For
each imaging modality, raw imaging data was saved at the
end of each imaging session and batch processed at a later
time, blinding the data analysis process to individual
tumor identity. Tumor size data calculated from fluores-
cence and ultrasound images was then compiled in a
spreadsheet for comparison and analysis. To determine
the correlation between imaging modalities, we com-
pared tumor size calculated from whole-body fluores-
cence images acquired using a single exposure time to
tumor size determined from ultrasound images. This
process yielded multiple correlation graphs, one for each
exposure time. The correlation coefficient R2 was calcu-
lated between ultrasound tumor area and whole-body flu-
orescence tumor area. P < 0.05 was considered significant.
Statistics were performed using Excel software (Microsoft
Corporation, Redmond, WA).
Gross and histologic examination of tissues
At necropsy, larger tumors were dissected away from the
normal pancreas and measured ex vivo using calipers to
determine three-dimensional size. A subset of small
tumors, those imageable by fluorescence and/or ultra-
sound but not apparent to the naked eye when looking at
the intact pancreas, were subjected to histologic examina-
tion for confirmation of imaging findings. Additional
tumors were processed for histological examination as
necessary to address specific anatomic and micro-ana-
tomic questions. Fresh tissues were placed in Bouin's fixa-
tive and processed using standard methods for paraffin
embedding and sectioning. Sections were stained used
hematoxylin and eosin and examined using a inverted
Nikon DE-300 fluorescence microscope equipped with a
Spot RD camera (Diagnostic Instruments, Inc., Sterling
Heights, MI).
Results and Discussion
Imaging systems
Figure 1 shows the imaging systems used in this study. The
Olympus OV100 Small Animal Imaging System (Figure
1A) contains an internal platform on which the anesthe-
tized mice are placed during imaging. The camera is posi-
tioned above the mice, and images are obtained in theBMC Cancer 2009, 9:106 http://www.biomedcentral.com/1471-2407/9/106
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same plane as the platform. A diagram of the Olympus
OV100 optical layout and additional details regarding the
OV100 have been previously published [14]. The Visual-
Sonics Vevo™ 770 In Vivo High-Resolution Micro-Imaging
System (Figure 1B) also has a platform on which anesthe-
tized mice are placed during imaging. The ultrasound
imaging probe yields images which are perpendicular to
the plane of the platform. We generated coronal images
for both fluorescence and ultrasound imaging modalities
for comparison of tumor size. Additional information
concerning the Vevo™ 770 is available from the Visual-
Sonics website http://www.visualsonics.com/products/
products_vevo770.htm.
Measurement of tumor size using fluorescence imaging 
and ultrasound imaging
Whole-body fluorescence imaging and ultrasound imag-
ing both allowed for the visualization and measurement
of orthotopic pancreatic tumor implants in vivo. Figure 2
shows the process used to evaluate and measure tumors.
A color camera was used to collect bright-field images of
the mice and color images of the RFP-expressing ortho-
topic tumor implants, which were imaged through the
intact skin (Figure 2B). Bright-field and fluorescence
images were overlaid to generate a composite image
showing the position of the fluorescent tumor relative to
the mouse (Figure 2A). For measurement of tumor size,
the color camera was replaced with a monochrome cam-
era capable of quantitative fluorescence imaging. Mono-
chrome images were analyzed using ImageJ software to
calculate the cross-sectional size in mm2, as shown in Fig-
ure 2C.
Figure 2G shows an ultrasound image slice of a small
orthotopic tumor implant. Vevo 770 software was used to
manually trace the borders of the tumor on the image and
to calculate tumor size in mm2, as shown in Figure 2H.
Following ultrasound and whole-body fluorescence imag-
ing, the abdominal cavities of sacrificed mice were opened
and examined, the pancreas was exposed, and the opened
abdominal cavity was subjected to fluorescence imaging.
Fluorescence-only images (Figure 2E), composite bright-
field and color fluorescence images (Figure 2D), and
Imaging hardware used in this comparison study Figure 1
Imaging hardware used in this comparison study. A. Olympus OV100 Small Animal Imaging System. B. VisualSonics 
Vevo™ 770 In Vivo High-Resolution Micro-Imaging System.BMC Cancer 2009, 9:106 http://www.biomedcentral.com/1471-2407/9/106
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Fluorescence and ultrasound imaging of orthotopic pancreatic tumor implants and measurement of tumor size Figure 2
Fluorescence and ultrasound imaging of orthotopic pancreatic tumor implants and measurement of tumor 
size. A-H. This mouse was imaged two weeks after orthotopic injection of a human pancreatic cell line (XPA-1) stably 
expressing red fluorescent protein (RFP). A-C. Evaluation of tumor size by whole body imaging of an anesthetized mouse. A. 
Bright field and color fluorescence images were overlaid to show the coronal image of the fluorescent tumor. B. Enlarged 
whole body fluorescence image of tumor. This image was obtained using a color (non-quantitative) fluorescence imaging cam-
era. C. Monochrome (quantitative) fluorescence image of the tumor shown in panels A and B. This coronal image was analyzed 
using ImageJ software to determine the cross-sectional size of the tumor in millimeters squared (mm2). D-F. Evaluation of 
tumor size at necropsy. D. Overlay of bright field and color fluorescence images showing the fluorescent tumor implant at 
necropsy. E. Enlarged color fluorescence-only image of the tumor as shown in D. F. As for panel C above, the cross-sectional 
size of the tumor shown in panels D and E was determined using ImageJ software. G. This ultrasound image of the pancreatic 
tumor mass was obtained using a Visual Sonics Vevo 770 small animal ultrasound imaging system. With the anesthetized mouse 
in a lateral position, the 40 MHz ultrasound transducer was oriented to obtain coronal image slices of the tumor. H. Image 
showing the tumor at its maximum cross sectional size in the coronal plane. Vevo 770 imaging software was used to determine 
the cross sectional size (in mm2) of the tumor.BMC Cancer 2009, 9:106 http://www.biomedcentral.com/1471-2407/9/106
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monochrome (quantitative) fluorescence images (Figure
2F) were generated. For small tumors, the size of the
tumor was calculated as described above from open or ex
vivo fluorescence images, using ImageJ software to deter-
mine tumor size in mm2. There is a very close correlation
between whole-body fluorescence and ultrasound imag-
ing for measurement of tumor size in vivo using this
approach. The somewhat larger tumor size determined at
necropsy for this tumor most likely reflects oblique imag-
ing of this elongate tumor.
Comparison of whole-body fluorescence imaging with 
ultrasound imaging for monitoring tumor growth over time
Figure 3A shows growth of an orthotopic pancreatic
tumor implant over a 4-week period following orthotopic
implantation of XPA-1-RFP human pancreatic tumor
cells. The graph demonstrates a high correlation between
whole-body fluorescence imaging and ultrasound imag-
ing for monitoring tumor growth over time. The four
images obtained using each imaging modality demon-
strate that the growing pancreatic tumor implants are
clearly visualized using both fluorescence and ultrasound
imaging. Figure 3B shows the data obtained from four
additional mice serially-imaged to monitor growth of
orthotopic pancreatic tumor implants. There was a high
degree of variability in the absolute size and the growth
kinetics of individual tumors between mice originally
injected with the same number of XPA-1-RFP tumor cells
(Figure 3B), independent of imaging modality.
Comparison of whole-body fluorescence imaging with 
ultrasound imaging for determination of tumor size over a 
range of tumor sizes
As expected, fluorescence images obtained using higher
exposure times yielded larger calculated tumor sizes.
Exposure times of 67 msec and 120 msec yielded correla-
tion slopes (m = 0.9349 and m = 1.1604, respectively)
which came closest to showing a perfect correlation
between imaging modalities for assessment of tumor size.
This data is shown in Figure 4. Whole-body fluorescence
and ultrasound imaging showed a strong correlation for
measurement of tumor size over a range of tumor sizes (R2
= 0.6627, P = 0.003 for an exposure time of 67 msec and
R2 = 0.6553, P = 0.003 for an exposure time of 120 msec).
Data were obtained from tumors of various sizes up to a
limiting size of about 150 mm2. Tumors > 150 mm2 were
too large to fit within a single ultrasound image frame and
would, therefore, have been difficult to measure by ultra-
sound imaging in this study. Tumor dimensions were
determined at necropsy on 22 tumors. Tumor volumes,
which were approximated using the formula for an ellip-
soid, were compared to tumor sizes determined by imag-
ing studies. In vivo imaging studies showed a strong
correlation with post mortem analysis for determination
of tumor size (R2 = 0.7782 and R2 = 0.6092 for ultrasound
imaging and fluorescence imaging, respectively; P < 0.001
for both).
Correlation of in vivo ultrasound imaging and ex vivo 
fluorescence imaging with final histopathology
Findings obtained from ultrasound imaging of live mice
and ex vivo fluorescence imaging of tumor implants at
necropsy were correlated with histopathologic findings, as
shown in Figure 5. The presence of a small (2.69 mm2)
tumor implant detected by ultrasound imaging of this
mouse (Figure 5A) was confirmed by ex vivo fluorescence
imaging of the pancreas. The histopathologic findings for
this tumor correlate perfectly with the ultrasound and ex
vivo fluorescence findings. A somewhat larger tumor (total
area 27.72 mm2) appeared to be bilobate in ultrasound
images (Figure 5B). The bilobate form of the tumor was
confirmed by ex vivo fluorescence imaging and well dem-
onstrated by histopathologic studies.
Strengths and weaknesses of whole-body fluorescence 
imaging and ultrasound imaging for evaluation of 
orthotopic pancreatic tumor implants
In this study, ultrasound imaging showed a modest
advantage over whole-body fluorescence imaging for
detection of small pancreatic tumor implants (tumors <
25 mm2, Figure 4). Ultrasound imaging of small implants
was facilitated by knowledge of their expected location
subjacent the spleen; ultrasound scanning was focused on
this area in search of tumor. In contrast, the spleen con-
cealed small orthotopic tumor implants lying directly
beneath it from whole-body fluorescence imaging. The
presence of these small tumors was verified by open or ex
vivo fluorescence imaging (Figure 2F). In this setting, the
high specificity of fluorescence imaging for RFP-express-
ing tumor cells proved an advantage, allowing detection
of small satellite tumor foci that were easily overlooked
using ultrasound imaging. Larger tumors, particularly
those with multiple lobes or convoluted surfaces, would
be difficult to measure by two-dimensional ultrasound
imaging and, therefore, were excluded from analysis.
These larger tumors were easily imaged by whole-body
fluorescence imaging.
Conclusion
In vivo imaging studies yield information that cannot be
obtained from postmortem analysis alone, such as tumor
growth rates, the time course of metastases, or tumor
response to experimental therapeutics. Whole-body fluo-
rescence imaging and ultrasound imaging are both nonin-
vasive imaging modalities with good sensitivity for
detection of orthotopic pancreatic tumor implants in
nude mice. The mice in this study tolerated repeated imag-
ing sessions well, which likely reflects the use of an inha-
lation anesthetic rather that an injectable one and the
noninvasiveness of the imaging modalities. The experi-BMC Cancer 2009, 9:106 http://www.biomedcentral.com/1471-2407/9/106
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mental findings presented herein are specific to the XPA-
1-RFP orthotopic pancreas tumor model, but our observa-
tions have general applicability. Both imaging modalities
should prove effective for preclinical studies of cancer pro-
gression in other orthotopic mouse models of cancer.
A number of factors should be considered when deciding
to use either fluorescence or ultrasound imaging methods
to monitor tumor growth in longitudinal studies of exper-
imental mouse models. Both imaging modalities require
that the skin overlying the imaged area be hairless. When
using hairy mice rather than nude mice, the hair should
be removed using a depilatory lotion prior to imaging.
Detection sensitivity falls off for both imaging modalities
when tumors are very small or lie deep within the abdo-
men. This limitation is particularly relevant to studies in
which the goal is to follow early stages of metastasis
through whole body imaging. In the orthotopic model of
human pancreatic cancer used this study, we implanted
fluorescent XPA-1-RFP cells, which stably express high lev-
Comparison of whole body fluorescence imaging and ultrasound imaging to monitor tumor growth over time in individual mice Figure 3
Comparison of whole body fluorescence imaging and ultrasound imaging to monitor tumor growth over time 
in individual mice. Whole-body fluorescence and ultrasound images were obtained on a weekly basis for a period of four 
weeks. Tumor measurements were determined as explained in the legend for Figure 2. A. The graph shows the growth of an 
orthotopic pancreatic-tumor implant in a single mouse (M1) as assessed by both whole-body fluorescence (FL) and ultrasound 
(US) imaging. The four corresponding ultrasound (upper row) and color fluorescence (lower row) images are shown below 
the graph with the calculated tumor sizes (mm2) for each image indicated. B. Graphical depictions of tumor growth over a four 
week period for an additional four mice (M2 thru M5) with orthotopic pancreatic tumor implants. Bar graphs shown in this fig-
ure depict single measurements taken at weekly timepoints. The graphs demonstrate a strong correlation between whole-body 
fluorescence and ultrasound imaging modalities for determination of tumor size.BMC Cancer 2009, 9:106 http://www.biomedcentral.com/1471-2407/9/106
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Correlation of whole body fluorescence imaging and ultrasound imaging for assessment of tumor size in mice with orthotopic  implants of fluorescently-labeled pancreatic tumor cells Figure 4
Correlation of whole body fluorescence imaging and ultrasound imaging for assessment of tumor size in mice 
with orthotopic implants of fluorescently-labeled pancreatic tumor cells. Mice harboring tumors of varying sizes (n = 
30) were imaged using both fluorescence and ultrasound imaging to assess tumor size. The resulting measurements (cross-sec-
tional area in mm2, determined as previously explained) for each tumor were graphed to determine how well the imaging 
modalities correlated for assessment of tumor size over a range of tumor sizes. We assessed tumor sizes at two exposure 
times, 67 msec and 120 msec, that gave clear visual images which were neither under-exposed nor over-saturated and analyzed 
these images to measure tumor size. A-B. Determination of tumor size from fluorescence images taken with either a 67-milli-
second exposure time (panel A) or a 120-millisecond exposure time (panel B). There is a strong correlation between fluores-
cence and ultrasound imaging modalities for assessment of tumor size over a range of tumor sizes at both exposure times. 
Both exposure times (67 msec and 120 msec) yielded similar values for R2 and P.BMC Cancer 2009, 9:106 http://www.biomedcentral.com/1471-2407/9/106
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Correlation of histopathology with ex vivo fluorescence and in vivo ultrasound images in mice with orthotopic implants of fluo- rescently-labeled pancreatic tumor cells Figure 5
Correlation of histopathology with ex vivo fluorescence and in vivo ultrasound images in mice with orthotopic 
implants of fluorescently-labeled pancreatic tumor cells. A. Ultrasound image of a small orthotopic tumor implant 
(upper left image; tumor indicated by arrow; Sp, spleen) whose presence was confirmed by ex vivo fluorescence imaging (upper 
middle image). The histopathologic findings correlated well with the ultrasound and ex vivo fluorescence findings, as shown here 
in this low power (1× magnification) hematoxylin- and eosin-stained permanent tissue section (upper right image). A higher 
magnification (100×) of the area bordered by the black rectangle in the low power image is also shown (lower image). B. Ultra-
sound imaging (upper left image) documented the bilobate tumor shown here, Ex vivo fluorescence imaging also demonstrated 
the bilobate tumor (upper middle image) contained within the pancreas. Histologic examination showed close juxtapositioning 
of dual tumor masses surrounded by a stretched capsule of normal pancreas (upper right image). This low power (1× magnifi-
cation) image also shows the adjacent spleen, which was removed with the pancreas as an organ block to aid in orientation of 
the fixed tissue for histologic examination. A higher magnification (100×) of the area bordered by the black rectangle in the low 
power image is shown enlarged below to better demonstrate the tumor mass and the normal pancreas tissue surrounding it.BMC Cancer 2009, 9:106 http://www.biomedcentral.com/1471-2407/9/106
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els of RFP. The bright expression of RFP, combined with
its favorable emission spectrum, facilitated detection of
tumors in whole-body fluorescence imaging studies. Sen-
sitivity for detection of fluorescent tumors will be dimin-
ished in cell lines showing less robust or less stable
expression of fluorescence and when using fluorophores
other than RFP for which autofluorescence by non-
expressing, normal host tissues is increased. On the other
hand, fluorophores with longer wavelength excitation
and/or emission spectra would be expected to have higher
tissue penetration than RFP. However, fluorescence inten-
sity and cellular toxicity are also variables which effect the
utility of a fluorophore for in vivo experimentation and
must also be evaluated.
In this study, orthotopic tumors arising from XPA-1-RFP
implants grew with well-demarcated borders yielding
sharp outlines on ultrasound images. This factor was help-
ful for identification and measurement of the tumors, par-
ticularly the smaller tumors. Tumors which grow with
infiltrating margins will be more difficult to identify and
to measure in ultrasound studies. As it is for fluorescence
imaging, tissue penetration is also an issue for ultrasound
imaging. Ultrasound transducers which produce longer
wavelength sound waves yield greater tissue penetration
but at the expense of imaging resolution. A variety of
transducers are available to optimize this balance. Differ-
ent transducers are used for small animal imaging as for
imaging of patients in the clinic. In both settings, tissue
penetration and imaging resolution counterbalance each
other. A variety of contrast agents are under investigation
for use in ultrasound imaging. These agents will likely
prove helpful in certain settings.
In short, the relative merits of each fluorescence and ultra-
sound imaging modalities will be influenced by character-
istics unique to each tumor-host model system. However,
our findings suggest that fluorescence imaging and ultra-
sound imaging modalities are complementary
approaches for monitoring tumor progression and treat-
ment response in preclinical studies using orthotopic
mouse models of human cancer.
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